Lupin and Avas launch NaMuscla in Italy
Avas will initially commercialise NaMuscla as a Class C (Tier 2), while Lupin negotiates with AIFA (Agenzia Italiana del Farmaco)…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
NaMuscla
Lupin partners with Celnova Pharma to distribute NaMuscla in Argentina and Colombia
NaMuscla (mexiletine) to be commercialised for the treatment of non-dystrophic myotonic disorders in adults
Lupin and Exeltis announce reimbursement approval of NaMuscla
Agreement enables sustainable patient access of the only EU-approved treatment for myotonia symptoms
Lupin signs distribution agreement with Medis for orphan drug NaMuscla
The agreement enables expanded patient access of the only EU-approved treatment for myotonia symptoms in non-dystrophic myotonic…
Lupin signs distribution agreement in EU territories for orphan drug NaMuscla
Reportedly, NaMuscula is the first and only licensed product for myotonia in adults with non-dystrophic myotonic disorders
Lupin aims to launch new products across geographies this fiscal
"Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market and commercialise our…